17h
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
GlobalData on MSN22h
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapyRegenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback